Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling

Prostate

Volumn 70, Issue 11, 2010, Pages 1201-1210

  Mink, Sheldon R ^a   Hodge, Amanda ^a   Agus, David B ^a   Jain, Anjali ^a   Gross, Mitchell E ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Prognostic marker; Signaling; Transcription

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BETA 2 MICROGLOBULIN; AR PROTEIN, HUMAN; RNA; SMALL INTERFERING RNA; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; GENE CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN TARGETING; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; AGED; BIOSYNTHESIS; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AGED; ANDROGENS; BETA 2-MICROGLOBULIN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77955932503     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21155     Document Type: Article

References (38)

1. Natarajan K, Li H, Mariuzza RA, Margulies DH. MHC class I molecules, structure and function. Rev Immunogenet 1999;1(1):32-46.
2. Huang WC, Havel JJ, Zhau HE, Qian WP, Lue HW, Chu CY, Nomura T, Chung LW. Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis inhuman prostate cancer cells. Clin Cancer Res 2008;14(17):5341-5347.
3. Nomura T, Huang WC, Seo S, Zhau HE, Mimata H, Chung LW. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol 2007;178(1):292-300.
4. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 2006;10(4):295-307.
5. Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 2007;110(8):3028-3035.
6. Huang WC, Wu D, Xie Z, Zhau HE, Nomura T, Zayzafoon M, Pohl J, Hsieh CL, Weitzmann MN, Farach-Carson MC, Chung LW. beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res 2006;66(18):9108-9116.
7. Nomura T, Huang WC, Zhau HE, Wu D, Xie Z, Mimata H, Zayzafoon M, Young AN, Marshall FF, Weitzmann MN, Chung LW. Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res 2006;12(24):7294-7305.
8. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23(32):8253-8261.
9. Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 2005;19(5):631-642. (Pubitemid 41219439)
10. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002;9(3):601-610.
11. Wang Q, Sharma D, Ren Y, Fondell JD. A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. J Biol Chem 2002;277(45):42852-42858.
12. Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res 2007;13(7):1979- 1986.
13. Xie J, Wang Y, Freeman ME III, Barlogie B, Yi Q. Beta 2-microglobulin as a negative regulator of the immune system: High concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 2003;101(10):4005-4012. (Pubitemid 36857879)
14. Rowley DR, Dang TD, McBride L, Gerdes MJ, Lu B, Larsen M. Beta-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor beta 1 action. Cancer Res 1995;55(4):781-786.
15. Jia L, KimJ, Shen H, Clark PE, TilleyWD,Coetzee GA. Androgen receptor activity at the prostate specific antigen locus: Steroidal and non-steroidal mechanisms. Mol Cancer Res 2003;1(5):385-392.
16. Nelson JD, Denisenko O, Bomsztyk K. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 2006;1(1):179-185.
17. Lee DK, Chang C. Endocrine mechanisms of disease: Expression and degradation of androgen receptor: Mechanism and clinical implication. J Clin Endocrinol Metab 2003;88(9):4043-4054.
18. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20(13):3001-3015.
19. Jia L, Coetzee GA. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus. Cancer Res 2005;65(17):8003-8008.
20. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007;27(3):380-392.
21. Huang W, Shostak Y, Tarr P, Sawyers C, Carey M. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem 1999;274(36):25756-25768. (Pubitemid 129530752)
22. Bianco FJ Jr, Wood DP Jr, Cher ML, Powell IJ, Souza JW, Pontes JE. Ten-year survival after radical prostatectomy: Specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer 2003;1(4):242-247.
23. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: Results of an International Consensus Conference of urologic pathologists. Adv Anat Pathol 2006;13(1):57-59.
24. Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schroder FH, Wildhagen MF, Scardino PT, Kattan MW. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 2002;20(4):951-956. (Pubitemid 34141837)
25. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18(19):3352-3359.
26. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, Fearn PA, Kattan MW. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98(10):715-717.
27. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21(2):383-391.
28. Cordon-Cardo C, Kotsianti A, Verbel DA, Teverovskiy M, Capodieci P, Hamann S, Jeffers Y, Clayton M, Elkhettabi F, Khan FM, Sapir M, Bayer-Zubek V, Vengrenyuk Y, Fogarsi S, Saidi O, Reuter VE, Scher HI, Kattan MW, Bianco FJ, Wheeler TM, Ayala GE, Scardino PT, Donovan MJ. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Investig 2007;117(7):1876-1883.
29. Chin JL, Reiter RE. Molecular markers and prostate cancer prognosis. Clin Prostate Cancer 2004;3(3):157-164. (Pubitemid 40051707)
30. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004;101(3):811-816.
31. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS.Amolecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006;103(29):10991-10996.
32. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1(2):203-209.
33. Shi C, Zhu Y, Su Y, Chung LW, Cheng T. Beta2-microglobulin: Emerging as a promising cancer therapeutic target. Drug Discov Today 2009;14(1-2):25-30.
34. Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 2004;22(3):179-184. (Pubitemid 39377910)
35. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005;95(3):497-505.
36. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006;99(2):392-401.
37. Paliouras M, Diamandis EP. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. Biol Chem 2008;389(6):773-780. (Pubitemid 352009405)
38. Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, Eblen ST, Paschal BM, Weber MJ. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 2006;20(3):503-515.